About Kezar Life Sciences, Inc.
https://www.kezarlifesciences.comKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
CEO
Christopher J. Kirk
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-10-30 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BB BIOTECH AG
Shares:1.22M
Value:$7.53M
BLACKROCK INC.
Shares:830.37K
Value:$5.12M
BML CAPITAL MANAGEMENT, LLC
Shares:720.79K
Value:$4.45M
Summary
Showing Top 3 of 50
About Kezar Life Sciences, Inc.
https://www.kezarlifesciences.comKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $11.49M ▼ | $-11.23M ▲ | 0% | $-1.53 ▲ | $-11M ▲ |
| Q2-2025 | $0 | $14.6M ▼ | $-13.7M ▲ | 0% | $-1.87 ▲ | $-13.16M ▲ |
| Q1-2025 | $0 | $17.63M ▼ | $-16.56M ▲ | 0% | $-2.27 ▲ | $-15.96M ▲ |
| Q4-2024 | $0 | $21.56M ▼ | $-20.22M ▲ | 0% | $-2.77 ▼ | $-19.57M ▲ |
| Q3-2024 | $0 | $21.95M | $-20.31M | 0% | $-0.28 | $-19.65M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $90.22M ▼ | $97.73M ▼ | $14.75M ▼ | $82.98M ▼ |
| Q2-2025 | $100.85M ▼ | $109.12M ▼ | $17.34M ▼ | $91.79M ▼ |
| Q1-2025 | $114.36M ▼ | $125.26M ▼ | $22.19M ▼ | $103.07M ▼ |
| Q4-2024 | $132.25M ▼ | $144.68M ▼ | $27.77M ▼ | $116.92M ▼ |
| Q3-2024 | $148.39M | $164.09M | $30.04M | $134.05M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.23M ▲ | $-9.83M ▲ | $15.71M ▲ | $-1.3M ▼ | $4.57M ▲ | $-9.83M ▲ |
| Q2-2025 | $-13.7M ▲ | $-12.79M ▲ | $11.4M ▼ | $-1.27M ▲ | $-2.63M ▲ | $-12.79M ▲ |
| Q1-2025 | $-16.56M ▲ | $-17.19M ▼ | $13.74M ▼ | $-1.3M ▼ | $-4.75M ▼ | $-17.2M ▼ |
| Q4-2024 | $-20.22M ▲ | $-16.82M ▲ | $23.74M ▼ | $47K ▲ | $6.89M ▲ | $-16.84M ▲ |
| Q3-2024 | $-20.31M | $-17.49M | $24.06M | $0 | $6.58M | $-17.51M |
CEO
Christopher J. Kirk
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-10-30 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BB BIOTECH AG
Shares:1.22M
Value:$7.53M
BLACKROCK INC.
Shares:830.37K
Value:$5.12M
BML CAPITAL MANAGEMENT, LLC
Shares:720.79K
Value:$4.45M
Summary
Showing Top 3 of 50